Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00391729 | A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) | PHASE2 | COMPLETED | 221 | — | — | Oct 1, 2006 | Jun 1, 2007 | Oct 18, 2011 | 23 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-089 | DRUG | Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks |
| Placebo | DRUG | Subjects will take placebo QD, BID for 4-6 weeks |
Inclusion Criteria: * Meet criteria for attention deficit hyperactivity disorder * Have voluntarily signed an informed consent form * Are between 18 and 60 years of age * Will use contraceptive methods during the study * Women must not be pregnant or breast-feeding * Must be in generally good healt...